Betul Gok Yavuz

Betul Gok Yavuz

Auto-generated profile, based on publicly available information

Betul Gok Yavuz

Department of Medicine, The University of Missouri, Columbia, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
BYBetul Gok Yavuz
Betul Gok Yavuz
EHElshad Hasanov
Elshad Hasanov
SLSunyoung S Lee
Sunyoung S Lee
YMYehia I Mohamed
Yehia I Mohamed
MCMichael A Curran
Michael A Curran
AKAhmed Omar Kaseb
Ahmed Omar Kaseb
Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths in the world. Multiple immunotherapeutic approaches have been investigated to date, and immunotherapy has become the new standard of care therapy in HCC. However, the current role of immunotherapy in HCC remains non-curative. Given this context, a high priority for oncology is understanding the biomarkers that predict clinical response to immunotherapy, have the potential to improve patient selection to maximize the clinical benefit, and spare unnecessary toxicity. In this review, we summarize the key predictive and prognostic biomarkers investigated in immunotherapy clinical trials in HCC and the emerging biomarkers to serve as a roadmap for future clinical trials. Biomarkers from tumoral tissues including PDL-1 expression, tissue infiltrating lymphocytes, tumor mutational burden (TMB) and specific immune signatures, and from peripheral blood including neutrophil-to-lymphocytes ratio, platelet-to-lymphocytes ratio, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and specific cytokines, along with gut microbiota are among the studied biomarkers to date in the HCC era. More integrative approaches, including mathematical biomarkers to predict immunotherapy outcomes, are yet to be studied in HCC.

27 September 2025 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
AAArif Akyildiz
Arif Akyildiz
BYBetul Gok Yavuz
Betul Gok Yavuz
RIRashad Ismayilov
Rashad Ismayilov
MBMuge Buyukaksoy
Muge Buyukaksoy
ESEmine Sena Sözen
Emine Sena Sözen
AKAhmed Omar Kaseb
Ahmed Omar Kaseb